Exactis Innovation

Exactis Innovation: Reflecting on a Decade of Impact Today, I share a deeply bittersweet update about Exactis Innovation. After ten transformative years as a cancer research network funded by the Business-Led National Centres of Excellence (BL-NCE) Program, we must announce that Exactis will close its doors early in the new year. Exactis began with a bold vision: to provide patients with access to molecular testing, opening the door to trials for targeted therapies when such testing was not yet standard. Over the years, we adapted, evolved, and ultimately became a trusted source of decision-grade real-world evidence for cancer care. What we’ve accomplished together: -Built a network of 16 cancer centers across six provinces and curated a databank of over 11,000 patients. -Partnered with Canada’s Drug Agency (CDA) to inform real-world oncology market access decisions. -Showcased the immense potential of a pan-Canadian collaboration in leveraging patient data for the greater good. These milestones were only possible because of the unwavering support of so many. To the patients who entrusted us with their data, the coordinators and PIs at our sites, the Exactis team, our Board, and our partners—thank you. Your commitment made our mission not just possible, but meaningful. As we face the financial realities that have brought us to this decision, we remain committed to ensuring our databank continues to serve research and improve outcomes in cancer care. We will share details about its availability for future use as soon as possible. Exactis has proven that Canada's patients, researchers, and institutions can unite to break down barriers and drive innovation. My hope is that this legacy inspires others to dream big and create the next chapter in cancer research. To those ready to envision an "Exactis 2.0," I wish you courage and success. Let’s continue striving for a future where real-world data empowers breakthroughs and transforms lives. With gratitude and hope, Kostas Trakas, PhD CEO, Exactis Innovation

It’s Time for Our RWEcap! Join Kostas and Lester as they reflect on the highlights of #WhatsWithRWE from 2024. In this special episode, they share their stand-out moments and revisit insightful clips from an incredible lineup of guests who enlightened and challenged us throughout the year. A heartfelt thank you to all our guests and listeners who’ve joined us on this journey to explore Canada’s healthcare system, Real-World Evidence, cutting-edge AI technologies, and much more. Happy Holidays, and here’s to an exciting year ahead! #podcast #RWE #AI #RWD #CanadianHealthcare

🎉 Thank you for 10 Years of Impact at Exactis Innovation! 🎉 This year marks a decade of dedication to improving cancer survivorship across Canada. At Exactis Innovation, our mission has been to empower the healthcare ecosystem with timely, data-driven insights by generating real-world evidence from cancer care data. With over 11,000 patients consenting and a great network of hospital partners across Canada, our team has built the most comprehensive pan-Canadian real-world dataset. None of this would have been possible without the incredible contributions of our community. To the doctors and coordinators at our hospital partners: thank you for your unwavering commitment to advancing patient care. To the patients who shared their journeys with us: your courage inspires everything we do. And to our passionate employees: thank you for your dedication to our mission of driving innovation and making a meaningful impact. A huge thank you to all have contributed to our mission! ******************************** 🎉 Merci pour les 10 ans d'impact chez Innovation Exactis ! 🎉 Cette année marque une décennie de dévouement à l'amélioration de la survie au cancer à travers le Canada. Chez Exactis Innovation, notre mission a été d'habiliter l'écosystème des soins de santé avec des aperçus opportuns et axés sur les données en générant des preuves du monde réel à partir des données sur les soins du cancer. Avec plus de 11 000 patients consentants et un grand réseau d'hôpitaux partenaires à travers le Canada, notre équipe a construit l'ensemble de données réelles pancanadien le plus complet. Rien de tout cela n'aurait été possible sans l'incroyable contribution de notre communauté. Aux médecins et aux coordonnateurs de nos partenaires hospitaliers : merci pour votre engagement inébranlable à faire progresser les soins aux patients. Aux patients qui ont partagé leur expérience avec nous : votre courage inspire tout ce que nous faisons. Et à nos employés passionnés : merci pour votre dévouement à notre mission, qui est de stimuler l'innovation et d'avoir un impact significatif. Un grand merci à tous ceux qui ont contribué à notre mission !

"In rural and lower socio-economic [status] groups, not only is lung cancer more common, it's also more deadly." Check out this short clip of #WhatsWithRWE with Dr. Paul Wheatley-Price, lung cancer specialist, who shares his insightful perspective on health equity in Canada. Dr. Wheatley-Price delves into the importance of The National Day for Truth and Reconciliation and the persistent challenges faced by Indigenous communities in accessing equitable cancer care, and how we can work toward better health outcomes for all Canadians. #HealthEquity #TruthAndReconciliation #IndigenousHealth #CancerCare #HealthcareAccess #Podcast

🎙️ Podcast Highlight: Understanding Drug Access in Canada In this episode, Dr. Paul Wheatley-Price, medical oncologist specializing in lung cancer at The Ottawa Hospital, provides an analysis of the drug approval and reimbursement process in Canada. He explores the complexities of the system, shedding light on where we can focus efforts to make meaningful improvements. Dr. Wheatley-Price also discusses the potential of initiatives like Project Orbis, which aim to accelerate the approval process for life-saving treatments. While these efforts are promising, significant barriers remain, often delaying timely access to essential #cancer drugs for patients who need them most. 🎧 Listen to the full episode here: https://lnkd.in/eZKY955J #Oncology #CancerCare #DrugAccess #Podcast #WhatsWithRWE

The poll results are in. Interestingly, 38% of respondents highlighted preventive care as a top priority. But what would a healthcare system that truly prioritized prevention look like? Right now, our public system focuses largely on treating diseases due to limited capacity. Imagine if we shifted the emphasis to preventing illness instead—fewer people might develop chronic conditions in the first place. Preventive care could include things like more primary care, changes in diet and exercise, physiotherapy, stress management, etc. But here’s the challenge: Measuring the impact of prevention is tough because the benefits often take years to appear and vary widely between individuals. What do you think? Should we invest more in preventive care despite the long-term outlook? Share your thoughts below! 👇

✨NEW EPISODE! We’re thrilled to welcome Dr. Paul Wheatley-Price, a leading medical oncologist at The Ottawa Hospital, associate professor at the University of Ottawa and past-president of Lung Cancer Canada.. Dr. Wheatley-Price dives into Canada’s drug approval process, shedding light on the challenges that can delay access to life-saving medications for #lungcancer patients. He shares: -His experiences as an oncologist navigating the system -Comparisons between Canada and other countries' approaches -Advocacy tips to improve patient access to treatments -Innovative solutions like OBAs and conditional funding Plus, he draws an unexpected (and chilling) parallel between our system and the hit show Squid Game. Don't miss it! Our YouTube channel: https://lnkd.in/eh7gGP-9 #WhatsWithRWE #Podcast #Cancer #Oncology #DrugAccess

Pleased to share this drug utilization study completed by the Canadian Cancer Real-world Evaluation team, in collaboration with Exactis, part of the Canada's Drug Agency Post-Marketing Drug Evaluation CoLab Network. Recent advances in non–small cell lung cancer (NSCLC) treatment have introduced targeted therapies for specific mutations, supplementing standard chemotherapy. However, it's unclear if patients previously treated with both can benefit from immune checkpoint inhibitors (ICIs). This study aimed to understand the current treatment patterns for patients with advanced NSCLC with actionable driver mutations, and to determine the feasibility of conducting a study to compare the effectiveness of ICIs and single-agent chemotherapy, among patients who had received driver mutation-targeted therapies as their first treatment. https://lnkd.in/gkN3jbJ6 #rwe #cancer #oncology #personalizedmedicine Ontario Health | Santé Ontario

Thanks for sharing our mission to represent Canadian data, Lester Poon and SOPHiA GENETICS! #RealWorldEvidence #RealWorldData #Cancer

We've been diving into one of the most exciting topics in healthcare reform today—value-based healthcare (#VBHC)! Recently, we had the chance to interview one of Canada’s leading voices in VBHC, Eva Villalba, M.B.A., MSc., VBHC Green Belt. 🎙️ 👉 Check out Eva's definition of VBHC here: https://lnkd.in/dvYcrJCB With so much discussion about how VBHC could transform our healthcare system, we want to hear from YOU: When you hear this term, what comes to mind first? Let’s spark a conversation on how VBHC can shape the future of healthcare. 💬 #ValueBasedHealthcare #HealthcareInnovation #Poll #WhatsWithRWE